GlassScriptPhysician profile
Jade Truong
NPI 1588913305
$3,078.69
in general payments reported to CMS, 2019-2025
24 companies · $936 in 2025
The $936 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $261 · 2023: $651 · 2024: $846 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,433.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $723.06 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $385.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.64 | 2021-2025 | Jardiance |
| Amgen INC. | $278.61 | 2023-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $194.22 | 2024-2025 | |
| Madrigal Pharmaceuticals | $147.49 | 2025 | Rezdiffra |
| Viiv Healthcare Company | $108.99 | 2024 | |
| Calliditas Therapeutics US INC. | $99.02 | 2025 | Tarpeyo |
| Amarin Pharma, INC. | $97.90 | 2021 | |
| Novo Nordisk INC | $97.12 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $84.29 | 2024-2025 | |
| Exact Sciences Corporation | $67.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $62.74 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $62.05 | 2024-2025 | |
| Glaxosmithkline, LLC. | $61.85 | 2023-2025 | Shingrix, Arexvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.85 | 2021 | |
| Cranial Technologies, INC | $37.85 | 2022-2023 | Doc Band |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.65 | 2023 | |
| Edwards Lifesciences Corporation | $33.19 | 2023 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $22.88 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $20.13 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $19.44 | 2025 | |
| Mannkind Corporation | $15.04 | 2022 | |
| Hologic Sales and Service, LLC | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.